Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Therapy-induced resistance remains a significant hurdle to achieve long-lasting responses and cures in cancer patients. We investigated the long-term consequences of genetically impaired angiogenesis by engineering multiple tumor models deprived of endoglin, a co-receptor for TGF-β in endothelial cells actively engaged in angiogenesis. Tumors from endoglin-deficient mice adapted to the weakened angiogenic response, and refractoriness to diminished endoglin signaling was accompanied by increased metastatic capability. Mechanistic studies in multiple mouse models of cancer revealed that deficiency for endoglin resulted in a tumor vasculature that displayed hallmarks of endothelial-to-mesenchymal transition, a process of previously unknown significance in cancer biology, but shown by us to be associated with a reduced capacity of the vasculature to avert tumor cell intra- and extravasation. Nevertheless, tumors deprived of endoglin exhibited a delayed onset of resistance to anti-VEGF (vascular endothelial growth factor) agents, illustrating the therapeutic utility of combinatorial targeting of multiple angiogenic pathways for the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907 · cited 1×
“Members of the TGF- family act pleiotropically on most, if not all, cell types in the body by engaging a hetero-tetrameric complex of type I and type II receptors (ten Dijke and Arthur, 2007; Massagué, 2008).”
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“In tumors, endoglin is selectively up-regulated on endothelial cells (Westphal et al., 1993; Burrows et al., 1995; Miller et al., 1999; Bernabeu et al., 2009), and in many different tumor types, including breast, colon, and lung carcinoma, abundant expression of endoglin is a predictor of poor…”
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621 · cited 3×
“The emergence of tumors resistant to treat-ment with VEGFR-blocking agents is characterized by increased metastatic spread consequential to a highly locally invasive phenotype (Casanovas et al., 2005; Pàez-Ribes et al., 2009).”
Self-citationDiscovery of Endothelial to Mesenchymal Transition as a Source for Carcinoma-Associated Fibroblasts
Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M., & Kalluri, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-3127 · Cited by 1,011
Pericytes limit tumor cell metastasis
Xian, X. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25705 · Cited by 345 · cited 1×
“…noted previously in conjunction with increased metastatic formation in RIP1-Tag2 mice deficient for a single or both copies of the gene encoding neural cell adhesion molecule (NCAM; Xian et al., 2006), raising the question of whether diminished expression of NCAM is part of the EndMT phenotype.”
Ebos, J. M. L., Lee, C. R., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0095 · Cited by 291
Lack of Primary Cilia Primes Shear-Induced Endothelial-to-Mesenchymal Transition
Egorova, A. D., Khedoe, P. P. S. J., Goumans, M.-J. T. H., Yoder, B. K., Nauli, S. M., ten Dijke, P., Poelmann, R. E., & Hierck, B. P. (2011) · Circulation Research · doi:10.1161/circresaha.110.231860 · Cited by 195
Self-citationALK1 as an emerging target for antiangiogenic therapy of cancer.
Cunha, S. I., & Pietras, K. (2011) · Blood · doi:10.1182/blood-2011-01-330142 · Cited by 184
Self-citationHu-Lowe, D. D., Chen, E., Zhang, L., Watson, K. D., Mancuso, P., Lappin, P., Wickman, G., Chen, J. H., Wang, J., Jiang, X., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1451 · Cited by 130
Cited by
Crossing the endothelial barrier during metastasis
Reymond, N., d'Água, B. B., & Ridley, A. J. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3628 · Cited by 922
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling
Wang, X., Abraham, S., McKenzie, J. A. G., Jeffs, N., Swire, M., Tripathi, V. B., Luhmann, U. F. O., Lange, C. A. K., Zhai, Z., Arthur, H. M., et al. (2013) · Nature · doi:10.1038/nature12345 · Cited by 539
Self-citationPeng, F., Setyawati, M. I., Tee, J. K., Ding, X., Wang, J., Nga, M. E., Ho, H. K., & Leong, D. T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0356-z · Cited by 480
Endothelial-to-Mesenchymal Transition in Cancer
Clere, N., Renault, S., & Corre, I. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00747 · Cited by 199
“To the same extend, hepatic and lung metastatic seeding is increased in pancreatic cancer mouse model upon endoglin deficiency-induced EndMT (Anderberg et al., 2013).”
BackgroundInfluential
Metadata
- Authors
- Anderberg, C., Cunha, S. I., Zhai, Z., Cortez, E., Pardali, E., Johnson, J. R., Franco, M., Páez-Ribes, M., Cordiner, R., Fuxe, J., Johansson, B. R., Goumans, M.-J., Casanovas, O., ten Dijke, P., Arthur, H. M., & Pietras, K.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-02-11
- Volume
- 210
- Issue
- 3
- Pages
- 563-579
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2154087679
- Cited by
- 135
- References
- 9
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. https://app.cochat.ai/papers/10.1084/jem.20120662
- The paper
- Anderberg, C., Cunha, S. I., Zhai, Z., Cortez, E., Pardali, E., Johnson, J. R., Franco, M., Páez-Ribes, M., Cordiner, R., Fuxe, J., Johansson, B. R., Goumans, M.-J., Casanovas, O., ten Dijke, P., Arthur, H. M., & Pietras, K. (2013). Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20120662
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.